Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Off-target binding remains a significant challenge in tau-PET neuroimaging. While off-targets including monoamine oxidase enzymes and neuromelanin-containing cells have been identified, recent studies indicated a relevant binding of novel tau tracers to melanin-containing structures. To date, little is known about the effect of melanocytes in the meninges on tracer signals in brain PET data. Thus, we aimed to identify the target structure causal for the frequently observed [F]PI-2620 PET signal in the vermis and adjacent cerebellar regions.
Methods: 274 participants underwent dynamic [F]PI-2620 tau-PET: 3/4R-tauopathies (n = 85), 4R-tauopathies (n = 147), tau-negative disease controls (n = 24), and healthy controls (n = 18). Standardized uptake value ratio (SUVR) and kinetic parameters including the distribution volume ratio (DVR), tracer clearance (k2) and relative perfusion (R1), were compared among the cohorts and sexes using the Automated Anatomical Labelling (AAL) atlas. Age and p-Tau levels in cerebrospinal fluid (CSF) were assessed for their relationship with vermal tau-PET signal. Furthermore, we combined autoradiographic and histochemical experiments on post-mortem brain tissue of deceased patients (n = 9).
Results: Male participants revealed higher mean vermal [F]PI-2620 DVR (0.95 ± 0.13; vs. females 0.88 ± 0.10, p < 0.0001). Sex-related differences were most pronounced in the 3/4R-tauopathy cohort (p < 0.0001). Mean SUVR, k2 and correlation analyses of kinetic parameters did not differ among groups. Histological assessments revealed co-localization of leptomeningeal pigmented cells with strong autoradiography signal spots within the vermal fissures. Tau-related autoradiography signals, age or p-Tau levels did not correlate significantly with tau-PET signals. Iron deposits did not cause relevant autoradiography signals in the vermis.
Conclusion: Leptomeningeal melanocytes are the primary target structure for [F]PI-2620 PET binding in anterior vermis, whereas iron and tau deposits do not contribute significantly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12316827 | PMC |
| http://dx.doi.org/10.1007/s00259-025-07199-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation and interpretation of DTI-ALPS, a proposed surrogate marker for glymphatic clearance, in a large population-based sample.
Alzheimers Res Ther
August 2025
Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Background: The diffusion tensor imaging along perivascular spaces index (DTI-ALPS), which measures diffusivity in the perivascular spaces along the medullary veins, has gained popularity and controversy as a surrogate marker of glymphatic clearance. The goal of this work is to automatically estimate DTI-ALPS in a large population-based sample, evaluate the correlates of the signal observed in the context of aging and dementia biomarkers, and evaluate its clinical usefulness.
Methods: We identified 2715 participants aged 30 + years in the population-based Mayo Clinic Study of Aging with diffusion MRI.
Pilot Study of [C]HY-2-15: A Mixed Alpha-Synuclein and Tau PET Radiotracer.
Cells
July 2025
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
A novel brain positron emission tomography (PET) radioligand, [C]HY-2-15, has potential for imaging alpha-synuclein aggregations in multiple system atrophy and misfolded tau proteins in tauopathies, based on its high binding affinity in disease brain tissue homogenates. Here, we demonstrate that [H]HY-2-15 has the capability to bind to aggregated alpha-synuclein in multiple system atrophy brain and tau aggregations in progressive supranuclear palsy and corticobasal degeneration brain tissues via in vitro autoradiography study. A first-in-human pilot multicenter clinical study recruited a total of 10 subjects including healthy controls and patients with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.
View Article and Find Full Text PDF[18F]PI-2620 Tau PET signal across the aging and Alzheimer's disease clinical spectrum.
Imaging Neurosci (Camb)
October 2024
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, United States.
[18F]PI-2620 is a second generation tracer that has shown high binding affinity for tau aggregation in Alzheimer's disease (AD). However, [18F]PI-2620 signal in a large sample spanning the healthy aging and AD clinical spectrum as well as the stability of signal across different acquisition time windows has not yet been examined. Here, amyloid negative (Aβ-) cognitively unimpaired (CU; n = 49), amyloid positive (Aβ+) CU (n = 37), CU individuals with unknown amyloid status (n = 5), mild cognitive impairment (MCI; n = 14), dementia due to AD (n = 19), and non-AD neurodegenerative disorder (n = 54) participants were scanned with [18F]PI-2620 using a 45-75 min and/or 60-90 min acquisition time window.
View Article and Find Full Text PDFMRI-free processing of tau PET images for early detection.
Imaging Neurosci (Camb)
November 2024
Departments of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States.
Tau positron emission tomography (PET) imaging in Alzheimer's Disease (AD) is becoming increasingly common to assesstau burden. MR images are often acquired to assist with processing of PET data, including for region-of-interest definitions in native space and for normalization to template space. However, in the real-world setting, corresponding MRIs may not be available and PET processing may require MRI-free pipelines.
View Article and Find Full Text PDFTest-retest performance of [ F]MK-6240 tau burden and relative delivery indices in cognitively normal older subjects using PET/MRI.
Imaging Neurosci (Camb)
December 2024
Department of Radiology, Massachusetts General Hospital, Boston, MA, United States.
Accurate interpretation of quantitative positron emission tomography (PET)outcomes hinges on understanding the test-retest variability (T-RT).Previous studies of the tau-PET ligand [F]MK-6240 reported adequateT-RT performance of tau burden estimates over a short-term 21-day and over alonger-term 6-month T-RT period, primarily involving Alzheimer's disease(AD) and cognitively normal (CN) subjects, respectively. However, several T-RTcharacteristics have not yet been reported, particularly in older CN (oCN)subjects.
View Article and Find Full Text PDF